|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Whereas six of the genes (maspin, SCCA1, SCCA2, hurpin, megsin and pAI-2) were commonly differentially expressed in primary lesions, each significantly more often in squamous cell tumours, maspin was identified as the most frequently over-represented sequence in both squamous cell carcinoma and adenocarcinoma.
|
14647462 |
2003 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that SCCA1 is mainly expressed in squamous cell carcinoma, keratinocyte and non-squamous cell carcinoma cell lines and that the ratio of SCCA1 to SCCA2 expression might be a novel marker for the detection of squamous cell carcinoma.
|
11182054 |
2001 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Also, weak SCCA-2 immunoreactivity is observed in the SCC lesions, but only SCCA-1 in uterine cervical specimens with nonspecific inflammation.
|
21274549 |
2011 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Squamous cell carcinoma antigens 1 and 2 (SCCA1 and 2, SERPIN B3 and B4), members of the ovalbumin serpin (ov-serpin)/clade B serpin family, were originally discovered as tumor-specific antigens and are used as tumor markers for various kinds of squamous cell carcinomas.
|
29642409 |
2018 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that the transcriptional regulation of SCCA1 and SCCA2 might differ among squamous cell carcinoma, keratinocyte and adenocarcinoma cells, and that SCCA1 promoter might be a potential target of gene therapy for squamous cell carcinoma.
|
11267667 |
2001 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This suggests that combined measurements of both serum SCCA1 and SCCA2 concentrations can be very useful for distinguishing sinonasal inverted papilloma from SCC.
|
30376194 |
2018 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data indicate that specific quantitation of the expression level of SCCA2 mRNA may be useful for the diagnosis and management of patients with squamous cell carcinoma.
|
10867615 |
2000 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Reverse transcription (RT)-PCR of the squamous cell carcinoma cell line showed the existence of a 156 base shorter transcript compared with that of SCCA1 cDNA.
|
11406281 |
2001 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The SCCA1 promoter was analyzed by dual luciferase assay and substituted with the E1A promoter to construct the oncolytic adenovirus to determine the squamous cell carcinoma-specific cell lysis.
|
20527047 |
2010 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study examined the effect of squamous cell carcinoma antigen 1 (SCCA1) and SCCA2 on TNF-alpha-induced cell death in human oral squamous cell carcinoma cell lines.
|
16006770 |
2005 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We recently found that the squamous cell carcinoma antigens 1 (SCCA1) and SCCA2 are novel biomarkers of bronchial asthma, downstream of IL-4 and IL-13.
|
16238792 |
2005 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
One of the SCCAs, SCCA1, has been suggested to play a role in the attenuation of apoptosis in vitro and in the augmentation of tumor growth in vivo.
|
11280721 |
2001 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Immunoreactivity of recombinant squamous cell carcinoma antigen and leupin/SCCA-2: implications for tumor marker detection.
|
10873412 |
2000 |
|
Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
T357A variant has a significantly higher frequency in nonencapsulated tumors than wild type SCCA1 (p = 0.034).The SCCA1, 2 mRNA is effective for detecting HCC and could be potentially applied in HCC diagnosis.
|
25150316 |
2014 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Examination of squamous cell carcinomas of the lung and head and neck showed that SCCA1 and SCCA2 were co-expressed in moderately and well-differentiated tumors.
|
10653592 |
2000 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Medulloblastomas downregulated immune recognition molecules MHC-I and CD1 d. Intriguingly, expression of granzyme inhibitors SERPINB1 and SERPINB4 was acquired in 23% and 50% of the tumors, respectively.
|
29399402 |
2018 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Radiation response of cervical tumour cell lines after SCCA1 expression or CRISPR/Cas9 knockout was evaluated by clonogenic survival assay.
|
29112685 |
2018 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
SERPINB3 (Squamous Cell Carcinoma Antigen, SCCA1) is a member of the ov-serpins, a serine protease inhibitors family expressed in many cell types including normal epithelium, leukocytes, tumors of epithelial origin and primary liver cancer.
|
19332150 |
2009 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
In conclusion, poor prognosis in EAC overexpressing SCCA1 is due to reduced tumor chemosensitivity as well as intratumoral immunity impairment, likely induced by this molecule.
|
30825353 |
2019 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical analysis of samples from two independent series of Italian and Korean patients with squamous cell carcinoma of the skin indicated a significant association between SCCA2 protein expression and younger age at tumor onset.
|
12702576 |
2003 |
|
Liver carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Initially identified as a serological marker for advanced squamous cell carcinomas of the cervix, SCCA1 has also been found to be associated with other cancer types of epithelial or endodermal origins such as lung cancer, head and neck cancer, melanoma, and hepatocellular carcinoma.
|
21576355 |
2011 |
|
Liver carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
T357A variant has a significantly higher frequency in nonencapsulated tumors than wild type SCCA1 (p = 0.034).The SCCA1, 2 mRNA is effective for detecting HCC and could be potentially applied in HCC diagnosis.
|
25150316 |
2014 |
|
Liver carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the diagnostic sensitivity and specificity of protein induced by vitamin K absence or antagonist-II (PIVKAII), Glypican-3 (GP3), Cystatin B (CSTB), squamous cell carcinoma antigen 1 (SCCA1) and hepatocyte growth factor (HGF) as potential tumour markers for HCC in patients with alcoholic liver cirrhosis (ALC) using imaging techniques (MSCT and MRI) as reference standards.
|
28766361 |
2018 |
|
Liver carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Furthermore, our data in this homogenous subset of patients- particularly that confirming no role for SCCA-1 - suggests that the choice of optimal biomarkers for HCC surveillance may be determined by the aetiology of underlying chronic liver disease.
|
18638391 |
2008 |
|
Liver carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
The clinical data published so far and reviewed in this article seemingly suggest that neither total serum SSCA or its isoform 1 (i.e., SCCA1) may be ready for the prime time for management of patients with HCC.
|
25840050 |
2015 |